可手术早期非小细胞肺癌立体定向体部放疗的多中心分析
本研究为回顾性队列研究,纳入2006—2015年接受根治性立体定向体部放疗(SBRT)的活检证实cT1-2N0M0非小细胞肺癌(NSCLC)患者,共952例,其中可手术408例(42.9%)、不可手术544例(57.1%)。可手术组2年局部失败率为9.7%,不可手术组为8.2%(p=0.36);区域及远处失败两组无统计学差异(p=0.55);可手术组总生存(OS)统计学上更高(p=0.04),无进展生存(PFS)无统计学差异(p=0.11)。作者认为上述结果可能有助于可手术患者与其多学科团队共同决策。
要点
- 952例接受SBRT的cT1-2N0M0 NSCLC中,可手术408例(42.9%),不可手术544例(57.1%)。
- 2年局部失败率:可手术组9.7%,不可手术组8.2%(p=0.36),两组无统计学差异。
- 可手术组OS统计学上更高(p=0.04),PFS无统计学差异(p=0.11),区域及远处失败无统计学差异(p=0.55)。
核心结论
- 作者认为,可手术NSCLC患者接受SBRT后OS高于不可手术患者,但疾病相关结局相似。
- 作者认为这些结果可能有助于可手术患者与其多学科团队进行共同决策。
研究设计与样本
- 多中心回顾性队列研究,纳入2006—2015年接受根治性SBRT、活检证实的cT1-2N0M0 NSCLC患者。
- 不可手术定义为病历记录了手术候选条件差并给出未切除的理由;可手术定义为病历记录患者拒绝手术或选择SBRT,且无不可手术的记录理由。
- 定义存在歧义和(或)可手术状态记录不明确者被排除;共纳入952例患者。
主要发现
- 952例中可手术408例(42.9%),不可手术544例(57.1%);中位随访22个月。
- 2年局部失败率:可手术组9.7% vs 不可手术组8.2%(p=0.36)。
- 区域及远处失败两组比较p=0.55,无统计学差异。
- 可手术组OS统计学上更高(p=0.04),PFS无统计学差异(p=0.11)。
- 可手术组1年、2年、3年OS分别为85.4%、66.2%、51.2%。
关键数值与推荐
- 局部失败与区域及远处失败采用Fine和Gray竞争风险回归分析,OS与PFS采用Kaplan-Meier法分析。
- 2年局部失败率:可手术组9.7% vs 不可手术组8.2%(p=0.36)。
- 区域及远处失败两组比较p=0.55。
- OS两组比较p=0.04;PFS两组比较p=0.11。
- 可手术组1年、2年、3年OS分别为85.4%、66.2%、51.2%。
临床怎么用
- 作者认为,上述结果可能更好地为可手术NSCLC患者与其多学科团队之间的共同决策提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although stereotactic body radiation therapy (SBRT) is the standard of care for inoperable early-stage non-small cell lung carcinoma (NSCLC), its role for medically operable patients remains controversial. To address this knowledge gap, we conducted a multi-institutional study to assess post-SBRT disease control and survival outcomes in medically operable patients. METHODS: We conducted a retrospective cohort study including patients with biopsy-proven cT1-2N0M0 NSCLC treated with definitive SBRT (2006-2015). Per patient charts, inoperability referred to documentation of poor surgical candidacy with a given rationale for lack of resection. Charts of operable patients contained documentation of patients refusing surgery or choosing SBRT, without a documented rationale for inoperability. Subjects were excluded in cases of ambiguity regarding the aforementioned definitions and/or lack of clearly documented operability status. Endpoints included local failure (LF) and regional-distant failure, both evaluated with Fine and Gray competing risks regression; Kaplan-Meier methodology analyzed overall survival (OS) and progression-free survival (PFS). RESULTS: Of 952 patients, 408 (42.9%) were operable, and 544 (57.1%) were inoperable. Median follow-up was 22 months. Two-year LF was 9.7% in operable patients and 8.2% in inoperable patients (p = 0.36). There was no statistical difference in regional-distant failure (p = 0.55) between cohorts. Operable patients experienced statistically higher OS (p = 0.04), but not PFS (p = 0.11). Respective 1-, 2-, and 3-year OS in operable patients were 85.4%, 66.2%, and 51.2%. CONCLUSIONS: Although patients with operable NSCLC experience higher OS than their inoperable counterparts, disease-related outcomes are similar. These results may better inform shared decision-making between medically operable patients and their multidisciplinary providers.
引用
- Kann BH, Verma V, Stahl JM, et al. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiother Oncol. 2019. PMID: 31005223. doi:10.1016/j.radonc.2019.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。